
Sarepta Continues Elevidys Shipments Amid FDA Concerns and Patient Safety Issues
Sarepta Therapeutics announced it will continue shipping its gene therapy Elevidys for Duchenne muscular dystrophy despite the FDA's request to halt shipments, indicating ongoing disputes over the drug's approval or safety concerns.



